Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Shikhar Mohan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California 94404, United States. Hauptthemen laut MEDLINE: Solubility, Fumarates, Drug Compounding, Chemistry, Pharmaceutical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
We report a novel utilization of a pH modifier as a disproportionation retardant in a tablet formulation. The drug molecule of interest has significant bioavailability challenges that require solubility enhancement. In addition to limited salt/cocrystal options, disproportionation of the potential salt(s) was identified as a substantial risk. Using a combination of Raman spectroscopy with chemometrics and quantitative X-ray diffraction in specially designed stress testing, we investigated the disproportionation phenomena. The learnings and insight drawn from crystallography drove the selection of the maleate form as the target API. Inspired by the fumarate form's unique stability and solubility characteristics, we used fumaric acid as the microenvironmental pH modulator. Proof-of-concept experiments with high-risk (HCl) and moderate-risk (maleate) scenarios confirmed the synergistic advantage of fumaric acid, which interacts with the freebase released by disproportionation to form a more soluble species. The resultant hemifumarate helps maintain the solubility at an elevated level. This work demonstrates an innovative technique to mediate the solubility drop during the "parachute" phase of drug absorption using compendial excipients, and this approach can potentially serve as an effective risk-mitigating strategy for salt disproportionation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California 94404, United States.
- Velexi Corporation, Burlingame, California 94010, United States.
ORCID-Profile: Chiajen Lai
Zitieren
APA
Mohan, S., Li, Y., Chu, K., De La Paz, L., Sperger, D., Shi, B., Foti, C., Rucker, V., & Lai, C. (2024). Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00166
Vancouver
Mohan S, Li Y, Chu K, De La Paz L, Sperger D, Shi B, et al. Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00166
BibTeX
@article{Mohan2024,
author = {Mohan, Shikhar and Li, Yi and Chu, Kevin and De La Paz, Liliana and Sperger, Diana and Shi, Bing and Foti, Chris and Rucker, Victor and Lai, Chiajen},
title = {Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00166}
}
EUVIMED